Can a smarter scan make liver testing more reliable?

NCT ID NCT06519331

Recruiting now Diagnosis Sponsor: Echosens Source: ClinicalTrials.gov ↗

First seen Aug 05, 2026 · Last updated Aug 06, 2026 · Updated 1 time

Summary

This trial is testing a new method for measuring liver stiffness using the FibroScan device, a non-invasive tool that helps assess liver health. About 153 adults with liver disease or suspected liver disease will take part across two French sites. The goal is to see if the new method gives more consistent readings within a single exam compared to the current standard approach.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Research FibroScan device
What this could lead to: If successful, this could lead to a more reliable, non-invasive way to measure liver stiffness, improving diagnosis and monitoring of liver disease.
What could go wrong: This is an early-stage device study, so the new method may not prove more consistent than the current approach. Results are preliminary and need further validation.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LIVER DISEASES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

liver disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LIVER DISEASES

Contacts and locations

Locations

Groupe Hospitalier Nord Essonne - Site Paris- Saclay
RECRUITING

Orsay, 91400, France
Hôpital Pitié-Salpêtrière
RECRUITING

Paris, Île-de-France Region, 75013, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.